The high PARP1-inhibitory activity of RSV makes it a promising candidate for the therapy of breast and ovarian cancers having the susceptibility gene mutation (BRCAm), where the use of synthetic PARP1 inhibitors is currently recommended. Here, PARP1 is linked to ovarian cancer.